Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

MDMA study probes oxytocin differences in autism

NCT ID NCT07555132

First seen May 06, 2026 · Last updated May 19, 2026 · Updated 3 times

Summary

This study looks at how a single dose of MDMA (the active ingredient in ecstasy) changes oxytocin levels in the blood of 40 adults—half with autism spectrum disorder and half without. The goal is not to treat autism but to understand if the brain's oxytocin system works differently in people with autism. Participants will receive both MDMA and placebo on separate visits to compare their body's response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital Basel, Endocrinology, Diabetes and Metabolism

    Basel, 4031, Switzerland

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.